Kymera Investor Presentation Deck

= Immunology-Inflammation Clinical Pipeline Programs with DC/IND's in 2023/24 Kymera's Pipeline of Novel Protein Degraders KYMERA Program IRAK4 IRAKIMID (IRAK4, Ikaros, Aiolos) STAT3 MDM2 = Oncology STAT3 Scaffolding Kinase Transcription factor IL4/13 Pathway Transcriptional Regulator Novel Glue Scaffolding Complex Indication(s) HS, AD, RA, others MYD88MT Tumors PTCL, LGL-L, CTCL, Solid Tumors Liquid & Solid Tumors Autoimmune & Fibrotic Diseases Psoriasis, IBD, Lupus, others AD, Asthma, COPD, EoE, PN Lupus, Auto-Ab Diseases, others Ovarian, Breast Ⓒ2023 KYMERA THERAPEUTICS, INC. Discovery IND Enabling Phase 1 00 KT-474 KT-413 KT-333 KT-253 Phase 2 Next Milestones HS and AD Ph2 Starts 4Q23 Clinical Activity 2023 Clinical Activity 2023 POM 2023 Rights KYMERA sanofi KYMERA KYMERA KYMERA KYMERA KYMERA KYMERA KYMERA KYMERA * *Option to participate equally in the development and commercialization of Sanofi-partnered programs in the US PAGE 7

View entire presentation